Kynam Capital Management, LP
- SEC CIK
- 0001907884
- Latest filing
- Aug 14, 2026
Holdings in Q4 2021
Holdings as of Dec 31, 2021, filed Feb 14, 2022. Long positions only.
- Positions
- 30
- No filing for Q3 2021
- Portfolio value
- $187.1M
- No filing for Q3 2021
Kynam Capital Management, LP did not file a 13F for Q3 2021, so these holdings cannot be compared with the previous quarter and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| GBTGlobal Blood Therapeutics, Inc. | COM | 992,949 | $29.1M | 15.5% | – | – | History |
| XENEXenon Pharmaceuticals Inc. | COM | 670,093 | $20.9M | 11.2% | – | – | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 956,165 | $20.9M | 11.2% | – | – | History |
| GOSSGossamer Bio, Inc. | COM | 1,016,857 | $11.5M | 6.1% | – | – | History |
| BIIBBiogen Inc. | COM | 40,000 | $9.60M | 5.1% | – | – | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 226,726 | $8.76M | 4.7% | – | – | History |
| AMRNAmarin Corp PLC | SPONS ADR NEW | 2,210,866 | $7.45M | 4.0% | – | – | History |
| VERAVera Therapeutics, Inc. | CL A | 253,449 | $6.77M | 3.6% | – | – | History |
| LQDALiquidia Corp | COM NEW | 1,366,836 | $6.66M | 3.6% | – | – | History |
| FOLDAmicus Therapeutics, Inc. | COM | 573,699 | $6.63M | 3.5% | – | – | History |
| VRDNViridian Therapeutics, Inc. | COM | 287,934 | $5.69M | 3.0% | – | – | History |
| TVTXTravere Therapeutics, Inc. | COM | 182,103 | $5.65M | 3.0% | – | – | History |
| FATEFate Therapeutics Inc | COM | 95,561 | $5.59M | 3.0% | – | – | History |
| PCVXVaxcyte, Inc. | COM | 211,483 | $5.03M | 2.7% | – | – | History |
| WVEWave Life Sciences, Inc. | SHS | 1,494,594 | $4.69M | 2.5% | – | – | History |
| MRUSMerus N.V. | COM | 122,158 | $3.88M | 2.1% | – | – | History |
| BNRBurning Rock Biotech Ltd | SPONSORED ADS | 382,464 | $3.65M | 1.9% | – | – | History |
| ZGNXZogenix, Inc. | COM NEW | 205,800 | $3.34M | 1.8% | – | – | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 293,799 | $2.75M | 1.5% | – | – | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 239,041 | $2.69M | 1.4% | – | – | History |
| MCRBSeres Therapeutics, Inc. | COM | 304,901 | $2.54M | 1.4% | – | – | History |
| CABACabaletta Bio, Inc. | COM | 644,583 | $2.44M | 1.3% | – | – | History |
| KRYSKrystal Biotech, Inc. | COM | 34,816 | $2.44M | 1.3% | – | – | History |
| PBYIPuma Biotechnology, Inc. | COM | 683,619 | $2.08M | 1.1% | – | – | History |
| Affimed N VN01045108 | COM | 364,033 | $2.01M | 1.1% | – | – | – |
| Radius Health, Inc.750469207 | COM NEW | 194,082 | $1.34M | 0.7% | – | – | – |
| COGTCogent Biosciences, Inc. | COM | 150,000 | $1.29M | 0.7% | – | – | History |
| AKUSAkouos, Inc. | COM | 99,008 | $842.0K | 0.5% | – | – | History |
| NGNENeurogene Inc. | COM | 147,000 | $709.0K | 0.4% | – | – | History |
| GYREGyre Therapeutics, Inc. | COM NEW | 110,991 | $101.0K | 0.1% | – | – | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.